Pharmacological agents

Donepezil is a potent reversible inhibitor of acetylcholinesterase that 

FIGURE 11.5. Mechanisms of action of cholinesterase inhibitors and memantine. 

Levodopa is the naturally occurring dopamine precursor and is considered the gold standard in the treatment of PD [44,45]. Pharmacologic 

Side effects of the dopamine receptor agonists include confusion, vomiting, nausea, dyspepsia, h q)otension, abdominal pain, insomnia. 

FIGURE 11.8. Structures selected dopamine receptor agonists (a) Bromocriptine, (b) Lisuride, (c) Piribedil, and (d) Ropinirole [52-55]. 

---

The first pharmacological agent shown to activate AMPK was 5-aminoimidazole-4-carboxamide (AICA) riboside, also known as acadesine. This adenosine analogue is taken up into cells by adenosine transporters and phosphoiylated by adenosine kinase to the mono-phosphorylated form, AICA ribotide or ZMP. ZMP accumulates inside cells to higher concentrations than the concentration of AICA riboside present in the medium, and it mimics both effects of AMP on AMPK system (allosteric activation and inhibition of... 

Schoepp DD, Jane DE, Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38 1431-1476... 

The text contains 58 chapters, which are divided into 11 units. Organization of the text in this manner allows the student to move about the text when these general areas are covered in the curriculum. While pharmacologic agents are presented in specific units, a disease may be treated with more than one type of drug, which may require consulting one or more units. 

Other drugs such as the neuroleptic, haloperidol, inhibit the induction of hsp70 mRNA in rodent neurons (Sharp et al.. 1992). Although this observation needs to be confirmed in the human population, it raises the possibility that an age-dependent defect in the production of HS proteins is exacerbated by a drug which is commonly used in demented elderly patients. The potential for certain pharmacologic agents to inhibit the HS response could increase the risk for untoward effects of atherosclerosis and hypoxia. A similar concern may be raised with certain calcium channel blockers which also have been found to reduce the synthesis of HS proteins in cardiac myocytes (Low-Friedrich and Schoeppe, 1991). 

Inhibitors of the catalytic activities of enzymes provide both pharmacologic agents and research tools for study of the mechanism of enzyme action. Inhibitors can be classified based upon their site of action on the enzyme, on whether or not they chemically modify the enzyme, or on the kinetic parameters they influence. KineticaUy, we distinguish two classes of inhibitors based upon whether raising the substrate concentration does or does not overcome the inhibition. 

The present chapter will address the following issues (1) a very brief overview on the properties of the different types of Cl -channels in the various mammalian cells (2) a short summary on what is known of Cl channels on a molecular basis (3) a discussion of pharmacological agents blocking the various Cl -channels and (4) a specific section dealing with the regulation of epithelial and maybe other Cl -channels. This entire area has been reviewed rather extensively in the recent past. A large number of references will be provided in order to keep this text concise. The entire field of Cl -channels in the central nervous system will only be touched upon to compare these channels to the Cl -channels in apolar cells and epithelia. 

The Ca channels that have been the most extensively studied are the voltage-dependent Ca channels. These channels are usually found in plasma or transverse tubule membranes. Voltage-dependent Ca channels open in response to an appropriate membrane depolarization. Several different types of voltage-dependent Ca channels have been described and are characterized by differences in their activation and inactivation sensitivities to voltage, their kinetic properties, and their sensitivities to activation or inhibition by a variety of pharmacological agents. 

So I think you can debate that issue about 99 or 95 percent depletion. I think that if you probe those animals with the proper pharmacological agents and proper environmental situation, you will pick up deficits. I think the lack of knowledge about what the serotonin systems do is the basis of the problem here. We don t know what the behavioral consequences of the serotonin depletion are. 

Pharmacological agents play a secondary role to electric cardioversion in unstable patients. 

What pharmacologic agents are appropriate to use at this time ... 

---